Cargando…

Comparative analysis of budesonide/formoterol and fluticasone/salmeterol combinations in COPD patients: findings from a real-world analysis in an Italian setting [Corrigendum]

Detalles Bibliográficos
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove Medical Press 2017
Materias:	Corrigendum
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5237589/ https://www.ncbi.nlm.nih.gov/pubmed/28138230 http://dx.doi.org/10.2147/COPD.S130231

Ejemplares similares

Comparative analysis of budesonide/formoterol and fluticasone/salmeterol combinations in COPD patients: findings from a real-world analysis in an Italian setting
por: Perrone, Valentina, et al.
Publicado: (2016)

Budesonide/Formoterol Anti-Inflammatory Reliever and Maintenance or Fluticasone Propionate/Salmeterol Plus as-Needed, Short-Acting β2 Agonist: Real-World Effectiveness in patients Without Optimally Controlled asthma (REACT) Study [Corrigendum]
Publicado: (2021)

Extrafine Beclomethasone/formoterol compared to Fluticasone/salmeterol Combination Therapy in COPD
por: Singh, Dave, et al.
Publicado: (2014)

Efficacy of indacaterol 75 μg versus fixed-dose combinations of formoterol-budesonide or salmeterol-fluticasone for COPD: a network meta-analysis
por: Cope, Shannon, et al.
Publicado: (2012)

Umeclidinium/Vilanterol Compared with Fluticasone Propionate/Salmeterol, Budesonide/Formoterol, and Tiotropium as Initial Maintenance Therapy in Patients with COPD Who Have High Costs and Comorbidities
por: Kalhan, Ravi, et al.
Publicado: (2021)

Health Care Utilization and Costs After Initiating Budesonide/Formoterol Combination or Fluticasone/Salmeterol Combination Among COPD Patients New to ICS/LABA Treatment
por: Davis, Jill R., et al.
Publicado: (2016)

Salmeterol/fluticasone stable-dose treatment compared with formoterol/budesonide adjustable maintenance dosing: impact on health-related quality of life
por: Price, David B, et al.
Publicado: (2007)

The bioavailability and airway clearance of the steroid component of budesonide/formoterol and salmeterol/fluticasone after inhaled administration in patients with COPD and healthy subjects: a randomized controlled trial
por: Dalby, Chris, et al.
Publicado: (2009)

Real-life effectiveness of fluticasone furoate/vilanterol after switching from fluticasone/salmeterol or budesonide/formoterol therapy in patients with symptomatic asthma: Relvar Ellipta for Real Asthma Control Study (RERACS study)
por: Shimizu, Yasuo, et al.
Publicado: (2020)

Salmeterol/fluticasone combination in the treatment of COPD
por: Chung, K F
Publicado: (2006)

The comparison of fluticasone propionate/formoterol with fluticasone propionate/salmeterol for paediatric asthma: a meta-analysis of randomized controlled trials
por: Jin, Xiaofen, et al.
Publicado: (2020)

The efficacy and safety of fluticasone propionate/formoterol compared with fluticasone propionate/salmeterol in treating pediatric asthma: a systematic review and meta-analysis
por: Guan, Renzheng, et al.
Publicado: (2019)

Effectiveness and Treatment Compliance of Salmeterol–Fluticasone Easyhaler(®) Among Patients with Asthma, COPD, or Asthma–COPD Overlap Syndrome: Real-World Study Findings
por: Tamási, Lilla, et al.
Publicado: (2022)

Budesonide–formoterol (inhalation powder) in the treatment of COPD
por: Ceylan, Erkan
Publicado: (2006)

Budesonide/Glycopyrronium/Formoterol: A Review in COPD
por: Heo, Young-A
Publicado: (2021)

Budesonide/Formoterol Anti-Inflammatory Reliever and Maintenance or Fluticasone Propionate/Salmeterol Plus As-Needed, Short-Acting β(2) Agonist: Real-World Effectiveness in pAtients without Optimally Controlled asThma (REACT) Study
por: Cheng, Shih-Lung, et al.
Publicado: (2020)

Nebulized step-down budesonide vs. fluticasone in infantile asthma: A retrospective cohort study
por: Wu, Zhimin, et al.
Publicado: (2020)

Risks of budesonide/formoterol for the treatment of stable COPD: a meta-analysis
por: Tang, Bin, et al.
Publicado: (2019)

Budesonide/formoterol combination in COPD: a US perspective
por: Sharafkhaneh, Amir, et al.
Publicado: (2010)

Correction to: Budesonide/Glycopyrronium/Formoterol: A Review in COPD
por: Heo, Young-A
Publicado: (2021)

Efficacy and onset of action of mometasone furoate/formoterol and fluticasone propionate/salmeterol combination treatment in subjects with persistent asthma
por: Bernstein, David I, et al.
Publicado: (2011)

Evaluation of a Therapeutic Interchange from Fluticasone/Salmeterol to Mometasone/Formoterol in Patients with Chronic Obstructive Pulmonary Disease
por: Yip, Elaine, et al.
Publicado: (2016)

Comparative effectiveness of budesonide/formoterol combination and fluticasone/salmeterol combination among chronic obstructive pulmonary disease patients new to controller treatment: a US administrative claims database study
por: Kern, David M, et al.
Publicado: (2015)

Onset of action of indacaterol in patients with COPD: Comparison with salbutamol and salmeterol-fluticasone
por: Balint, Beatrix, et al.
Publicado: (2010)

The role of fluticasone propionate/salmeterol combination therapy in preventing exacerbations of COPD
por: Yawn, Barbara P, et al.
Publicado: (2010)

Fluticasone/formoterol combination therapy is as effective as fluticasone/salmeterol in the treatment of asthma, but has a more rapid onset of action: an open-label, randomized study
por: Bodzenta-Lukaszyk, Anna, et al.
Publicado: (2011)

Comparative efficacy of indacaterol 150 μg and 300 μg versus fixed-dose combinations of formoterol + budesonide or salmeterol + fluticasone for the treatment of chronic obstructive pulmonary disease – a network meta-analysis
por: Cope, Shannon, et al.
Publicado: (2011)

The Efficacy and Safety of Budesonide/Glycopyrronium/Formoterol in the Treatment of COPD in the Elderly
por: Guo, Min, et al.
Publicado: (2022)

Role of the fixed combination of fluticasone and salmeterol in adult Chinese patients with asthma and COPD
por: Gao, Jinming, et al.
Publicado: (2015)

Umeclidinium/vilanterol versus fluticasone propionate/salmeterol in COPD: a randomised trial
por: Singh, Dave, et al.
Publicado: (2015)

Cost-effectiveness of combination fluticasone propionate–salmeterol 250/50 μg versus salmeterol in severe COPD patients
por: Dalal, Anand A, et al.
Publicado: (2010)

Clinical and cost effectiveness of switching asthma patients from fluticasone-salmeterol to extra-fine particle beclometasone-formoterol: a retrospective matched observational study of real-world patients
por: Price, David, et al.
Publicado: (2013)

Triple therapy with salmeterol/fluticasone propionate 50/250 plus tiotropium bromide improve lung function versus individual treatments in moderate-to-severe Japanese COPD patients: a randomized controlled trial – Evaluation of Airway sGaw after treatment with tripLE [Corrigendum]
Publicado: (2016)

Comparison of fluticasone propionate and budesonide on COPD macrophage and neutrophil function
por: Belchamber, Kylie BR, et al.
Publicado: (2018)

188 Efficacy Comparison of Mometasone Furoate/Formoterol Versus Fluticasone Propionate/Salmeterol Combination Therapies in Subjects With Persistent Asthma: Noninferiority and Onset-of-Action Findings
por: Bernstein, David, et al.
Publicado: (2012)

Fluticasone propionate/formoterol for COPD management: a randomized controlled trial
por: Papi, A, et al.
Publicado: (2017)

Non-inferiority efficacy comparison of mometasone furoate/formoterol versus fluticasone propionate/salmeterol combination therapies in subjects with persistent asthma
por: Bernstein, David I, et al.
Publicado: (2010)

24-Hour Serial Spirometric Assessment of Once-Daily Fluticasone Furoate/Umeclidinium/Vilanterol Versus Twice-Daily Budesonide/Formoterol in Patients with COPD: Analysis of the FULFIL Study
por: Lipson, David A., et al.
Publicado: (2020)

Early efficacy of budesonide/formoterol in patients with moderate-to-very-severe COPD
por: Calverley, Peter M, et al.
Publicado: (2016)

Retracted: The Efficacy and Safety of Budesonide/Glycopyrronium/Formoterol in the Treatment of COPD in the Elderly
por: Imaging, Contrast Media & Molecular
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_ikm8bdnoiotq9jmqjol35d9puq